Introduction {#H1-1-ZOI200329}
============

In response to the opioid epidemic, clinicians and patients are increasingly seeking alternatives to opioids for the management of musculoskeletal conditions. Centrally acting skeletal muscle relaxants (SMRs), such as baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, orphenadrine, and tizanidine, are labeled for acute musculoskeletal conditions including spasms and lower back pain; they are used off-label for neuropathic pain, chronic noncancer pain, temporomandibular disorder pain, and numerous nonpain conditions.^[@zoi200329r1]^ A 2003 systematic review concluded that SMRs are effective for acute low back pain (although their comparative effectiveness vs analgesics or nonsteroidal anti-inflammatory drugs for acute low back pain is unknown), the evidence for chronic low back pain is less convincing, and SMRs must be used with caution because of central nervous system adverse effects, such as drowsiness and dizziness.^[@zoi200329r2]^ Because of the lack of evidence regarding the long-term efficacy and safety of SMRs and the unquantified risk of abuse, dependence, and overdose,^[@zoi200329r1],[@zoi200329r3]^ recommendations generally limit the use of SMRs to a maximum duration of 2 to 3 weeks.^[@zoi200329r4]^ Despite such recommendations, a 1988-1994 study found that 44.5% of people taking SMRs were continuously treated for longer than 1 year.^[@zoi200329r5]^ Carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol, metaxalone, and orphenadrine are all considered potentially inappropriate medications in older adults,^[@zoi200329r6],[@zoi200329r7]^ in whom these agents are associated with sedation, cognitive impairment, and fracture.^[@zoi200329r8]^ An additional concern regarding the inappropriate use of SMRs is the potential for drug-drug interactions, particularly with opioids.^[@zoi200329r9]^

We sought to characterize national trends in SMR prescribing, both overall and in older adults, and to examine the concomitant prescribing of SMRs with opioids. Therefore, we examined nationally representative data from the National Ambulatory Medical Care Survey (NAMCS) for the 12-year period spanning from 2005 to 2016.

Methods {#H1-2-ZOI200329}
=======

We conducted a retrospective cross-sectional analysis of SMR prescribing using publicly available NAMCS data from January 2005 to December 2016. NAMCS is a US-based, annual survey of non--federally funded office-based physicians engaged in direct patient care.^[@zoi200329r10]^ Survey data are collected from sampled health care professionals by trained proctors. Office visit records are weighted based on the most recently available census data to provide a nationally representative view of all ambulatory care visits in the United States. The survey captures information about the office visit, such as the reason for the encounter and diagnoses, medications, and demographic information about the patient, as well as information about the provider and their practice.

We identified all office visits in which an SMR was recorded as either newly prescribed or continued ongoing drug therapy, referred to herein as an SMR visit. To limit the data set to records of interest, we generated a list of Lexicon Plus (Cerner Multum Inc) drug identification codes for baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, orphenadrine, and tizanidine. From these records, we extracted visit information, patient demographic characteristics, and record weights to generate national estimates. We examined the total number of visits per year; the race, ethnicity, and sex of the patient; and the region of the visit. Furthermore, we stratified counts by SMR agent and whether the SMR was newly prescribed or continued drug therapy.

We identified patients who were newly prescribed an SMR during the recorded visit by linking the new or continued status of reported medications (NCMed) variable to the SMR drug identification code. The NCMed variable indicates whether the medication was newly prescribed during the office visit or the patient was instructed to continue the medication as a part of their ongoing drug therapy. We examined the number of visits per year, the patient's primary reason for the office visit, and all recorded diagnoses. All concomitant medications were examined for new SMR visits, and concomitant opioids were examined for continued SMR visits. A list of variables used, corresponding NAMCS variable names, and the population in which they were examined are presented in eTable 1 in the [Supplement](#note-ZOI200329-1-s){ref-type="supplementary-material"}. For variables permitting multiple entries per visit, we included all entries without regard to ordering, eg, using all 5 diagnosis fields recorded in the 2016 survey.

We conducted analyses using the Statistical Package for Social Scientists, version 25 (IBM Corp) from August 21, 2018, to July 18, 2019. The University of Pennsylvania's Office of Regulatory Affairs determined that this research did not require institutional review board oversight because the NAMCS is a publicly available data set. This article complies with the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline for cross-sectional studies.^[@zoi200329r11]^

Results {#H1-3-ZOI200329}
=======

Patient demographic characteristics for SMR visits are shown in [Table 1](#zoi200329t1){ref-type="table"}. The cross-sectional analysis included a total of 314 970 308 office visits (mean \[SD\] age, 53.5 \[15.2\] years; 194 621 102 \[61.8%\] men and 120 349 206 \[38.2%\] women). In 2016, there were 30 730 262 (95% CI, 30 626 464-30 834 060) US ambulatory care visits in which an SMR was either newly prescribed or continued as ongoing therapy. Patients prescribed an SMR in 2016 tended to be female (58.2% \[95% CI, 57.9%-58.6%\] women vs 41.8% \[95% CI, 41.4%-42.1%\] men). Racial demographic characteristics for SMR users in 2016 were as follows: 53.7% white (95% CI, 53.4%-54.0%), 10.2% African American (95% CI, 9.7%-10.6%), 1.2% Asian (95% CI, 1.0%-1.5%), and 2.2% Native American or Alaska Native (95% CI, 2.0%-2.5%). There were no data available for Native Hawaiians, and 1.5% (95% CI, 1.3%-1.8%) of patients had more than 1 race reported. As shown in eTable 2 in the [Supplement](#note-ZOI200329-1-s){ref-type="supplementary-material"} and [Figure 1](#zoi200329f1){ref-type="fig"}, the number of US office visits in which an SMR was either newly prescribed or continued doubled from 15.5 million (95% CI, 15.4-15.6 million) visits in 2005 to 30.7 million (95% CI, 30.6-30.8 million) visits in 2016. During this 12-year period, the number of office visits resulting in new SMR prescriptions remained relatively stable at approximately 6 million (95% CI, 6.0-6.3 million) per year, whereas office visits for continued SMR drug therapy tripled from 8.5 million (95% CI, 8.4-8.5 million) to 24.7 million (95% CI, 24.6-24.8 million).

###### Demographic Distribution[^a^](#zoi200329t1n1){ref-type="table-fn"} of Patients in All SMR Office Visits, 2005-2016

  Variable                           Year                                                                                                                                                                                                             
  ---------------------------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------
  Sex                                                                                                                                                                                                                                                 
  Female                             61.9 (61.5-62.3)   58.1 (57.7-58.3)   61.2 (60.9-61.4)   65.4 (65.0-65.6)   67.3 (67.0-68.5)   62.9 (62.7-63.1)   65.7 (65.5-65.9)   61.0 (60.9-61.1)   59.0 (58.9-59.1)   65.2 (65.0-65.2)   57.5 (54.2-60.7)   58.2 (57.9-58.6)
  Male                               38.1 (37.7-38.6)   41.9 (41.6-42.3)   38.9 (38.6-39.1)   34.6 (34.3-34.9)   32.7 (32.4-32.9)   37.1 (36.8-37.3)   34.3 (34.0-35.5)   38.9 (38.9-39.1)   41.0 (40.9-41.1)   34.8 (34.7-35.0)   42.5 (42.0-43.0)   41.8 (41.4-42.1)
  Age, y                                                                                                                                                                                                                                              
  \<15                               0.7 (0.4-1.1)      1.0 (0.6-1.4)      0.2 (0.00-0.4)     0.9 (0.7-1.1)      0.5 (0.3-0.8)      0.2 (0.1-0.2)      1.2 (09-1.3)       0.7 (0.1-1.5)      0.4 (0.3-0.5)      0.6 (0.6-0.7)      0.3 (0.2-0.4)      0.3 (0.1-0.5)
  15-24                              7.4 (7.0-7.8)      8.7 (8.4-9.1)      5.3 (5.0-5.6)      3.4 (3.1-3.7)      2.5 (2.3-2.7)      4.2 (3.9-4.5)      2.6 (2.3-2.8)      3.7 (3.6-3.8)      3.6 (3.5-3.7)      2.9 (2.2-3.1)      1.8 (1.4-2.2)      4.1 (3.7-4.4)
  25-44                              31.2 (30.8-31.7)   33.8 (33.4-34.0)   37.2 (36.8-37.4)   32.4 (32.1-32.7)   26.8 (26.6-27.0)   28.2 (27.9-29.3)   29.1 (28.9-29.3)   26.8 (26.7-26.9)   23.3 (23.1-23.3)   24.7 (24.6-24.8)   21.0 (20.6-21.3)   24.9 (24.6-25.2)
  45-64                              41.8 (40.9-42.0)   42.7 (42.2-43.0)   41.6 (41.3-41.8)   42.6 (42.3-42.9)   52.4 (52.2-52.7)   50.4 (50.2-50.7)   49.4 (49.1-49.6)   49.1 (49.0-49.2)   51.9 (51.8-52.0)   49.3 (48.6-49.5)   48.7 (48.3-49.0)   48.5 (48.2-48.9)
  ≥65                                16.4 (15.9-16.8)   17.6 (16.2-17.9)   15.8 (15.4-16.0)   20.7 (20.4-21.0)   17.8 (17.5-18.3)   17.0 (16.8-17.3)   17.8 (17.6-17.9)   19.7 (19.6-19.7)   20.9 (20.7-21.0)   22.5 (22.4-22.6)   28.3 (27.8-28.7)   22.2 (21.8-22.6)
  Race/ethnicity                                                                                                                                                                                                                                      
  White                              87.8 (87.4-88.2)   84.3 (83.9-84.6)   57.7 (57.5-57.9)   56.2 (55.9-56.5)   69.4 (69.1-69.7)   66.3 (66.0-66.8)   65.3 (65.0-65.4)   56.7 (56.6-56.8)   58.6 (58.5-58.7)   64.7 (64.5-64.8)   60.4 (60.1-60.8)   53.7 (53.3-54.0)
  African American                   10.3 (9.9-10.7)    12.7 (12.3-13.0)   10.3 (9.9-10.6)    10.1 (9.8-10.4)    11.2 (10.9-11.5)   13.7 (13.4-13.9)   8.8 (8.4-9.0)      7.9 (7.8-8.0)      10.8 (10.6-10.9)   7.7 (7.6-7.8)      11.5 (11.2-11.7)   10.2 (9.7-10.6)
  Asian                              1.4 (1.1-1.7)      1.3 (0.9-1.5)      1.0 (0.7-1.3)      1.1 (0.9-1.2)      0.7 (0.5-0.8)      0.3 (0.2-0.4)      1.7 (1.0-2.0)      1.1 (1.1-1.3)      1.8 (1.2-2.0)      2.2 (2.2-2.7)      0.4 (2.8-6.1)      1.2 (1.0-1.5)
  Native Hawaiian                    NR                 0.9 (0.7-1.1)      NR                 NR                 NR                 NR                 NR                 0.2 (0.0-0.3)      0.8 (0.0-0.1)      1.3 (1.0-1.4)      NR                 NR
  Native American or Alaska Native   NR                 2.2 (0.5-1.3)      0.4 (0.1-0.5)      NR                 0.1 (0.0-0.2)      0.2 (0.1-0.2)      0.4 (0.2-0.5)      0.3 (0.2-0.4)      0.2 (0.1-0.2)      0.7 (0.6-0.8)      0.2 (0.1-0.3)      2.2 (2.0-2.5)
  \>1 Race/ethnicity reported        NR                 0.1 (0.0-0.1)      NR                 0.7 (0.0-0.1)      0.3 (0.0-0.4)      NR                 NR                 0.3 (0.2-0.4)      0.2 (0.1-0.3)      0.3 (0.2-0.3)      NR                 1.5 (1.3-1.8)

Abbreviations: NR, not reported; SMR, skeletal muscle relaxant.

Values are expressed as percentage (95% CI).
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Adults older than 65 years accounted for 22.2% (95% CI, 21.9%-22.6%) of SMR visits in 2016, although this group accounted for just 14.5% of the US population.^[@zoi200329r12]^ In 2016, the demographic characteristics of the other age groups were as follows: 0.3% (95% CI, 0.1%-0.5%) younger than 15 years, 4.1% (95% CI, 3.7%-4.4%) aged 15 to 24 years, 24.9% (95% CI, 24.6%-25.2%) aged 25 to 44 years, and 48.5% (95% CI, 48.2%-48.9%) aged 45 to 65 years. As shown in [Figure 2](#zoi200329f2){ref-type="fig"}, the proportion of visits that were SMR visits among patients 65 years and older increased 3-fold (from 1.3 SMR visits \[95% CI, 1.0-1.7\] per 100 office visits in 2005 to 4.3 SMR visits \[95% CI, 4.1-4.6\] per 100 office visits in 2016). The prescription of SMRs to older adults considered potentially inappropriate medications in this population (ie, carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, and orphenadrine) approximately doubled from 2.2 million (95% CI, 2.1-2.4 million) office visits in 2005 to 4.3 million (95% CI, 4.2-4.5 million) office visits in 2016.

![National SMR Utilization Rates Among Adults Aged 65 Years or Older, Stratified by New vs Continued Use, 2005-2016\
SMR indicates skeletal muscle relaxant.](jamanetwopen-3-e207664-g002){#zoi200329f2}

The most common diagnoses between 2005 and 2015 reported for new SMR visits are shown in [Table 2](#zoi200329t2){ref-type="table"}; the diagnosis coding system used for the NAMCS data shifted from the *International Classification of Diseases, Ninth Revision, Clinical Modification* to the *International Classification of Diseases, Tenth Revision, Clinical Modification* in 2016. The most common diagnoses during these visits were related to back pain and other musculoskeletal conditions; this pattern was maintained in 2016. As shown in [Table 2](#zoi200329t2){ref-type="table"}, among new SMR visits, hydrocodone-acetaminophen was the most common concomitant therapy. Other analgesics, such as ibuprofen, naproxen, and tramadol, were also commonly used. As shown in eTable 3 in the [Supplement](#note-ZOI200329-1-s){ref-type="supplementary-material"}, in 2016, 67.2% (95% CI, 62.0%-72.5%) of continuing SMR visits recorded concomitant therapy with an opioid, in contrast to 10.3% (95% CI, 9.8%-13.2%) of all ambulatory care visits nationally.

###### Visit Diagnoses (2005-2015[^a^](#zoi200329t2n1){ref-type="table-fn"}) and Concomitant Medications (2005-2016) Among New SMR Visits

  Variable                                                                                 Office visits, No. (95% CI)
  ---------------------------------------------------------------------------------------- ------------------------------------
  Diagnosis (*ICD-9-CM* code) (n = 78 671 742)[^b^](#zoi200329t2n2){ref-type="table-fn"}   
  Other and unspecified disorders of back (724.9)                                          26 496 352 (25 635 583-27 357 121)
  Sprains and strains of other and unspecified parts of back (847.9)                       10 148 115 (9 559 679-10 736 551)
  Spinal stenosis in cervical region (723.0)                                               8 205 661 (7 448 293-8 963 029)
  Other disorders of soft tissues (729.99)                                                 6 512 583 (5 996 830.56-7 028 335)
  Essential hypertension (401.1)                                                           6 049 615 (5 708 365-6 390 866)
  Intervertebral disc disorders (722.90)                                                   6 030 779 (5 425 636-6 635 922)
  Disorders of muscle, ligament, and fascia (728.79)                                       4 585 666 (4 254 719-4 916 613)
  Anxiety state (300.0)                                                                    3 167 519 (2 303 704-4 031 334)
  Other and unspecified disorders of joint (719.98)                                        2 989 405 (2 688 389-3 290 421)
  Disorders of lipoid metabolism (272.9)                                                   2 694 600 (2 362 481-3 026 719)
  Concomitant medication (n = 84 850 041)[^c^](#zoi200329t2n3){ref-type="table-fn"}        
  Hydrocodone-acetaminophen                                                                14 096 447 (13 380 518-14 812 376)
  Ibuprofen                                                                                12 531 204 (12 004 039-13 058 369)
  Naproxen                                                                                 9 820 338 (9 321 411-10 319 265)
  Tramadol                                                                                 5 011 229 (4 680 556-5 341 902)
  Lisinopril                                                                               4 208 202 (1 105 116-7 311 288)
  Meloxicam                                                                                4 069 328 (3 556 643-4 582 013)
  Aspirin                                                                                  3 969 403 (3 649 823-4 288 983)
  Omeprazole                                                                               3 927 795 (3 455 672-4 399 919)
  Albuterol                                                                                3 781 380 (3 376 754-4 186 006)
  Diclofenac                                                                               3 752 475 (3 545 994 -3 958 956)

Abbreviations: *ICD-9-CM*, *International Classification of Diseases, Ninth Revision, Clinical Modification*; SMR, skeletal muscle relaxant.

2016 excluded because of transition to *International Classification of Diseases, Tenth Revision, Clinical Modification*.

Among all new SMR office visits from 2005 to 2015.

Among all new SMR office visits from 2005 to 2016.

[Table 3](#zoi200329t3){ref-type="table"} shows the number of office visits and age-standardized rates of SMR visits for 2005 and 2016 stratified by geographic region and by new vs continued SMR. In the Northeast, age-standardized new SMR visit rates changed by −33.4% (95% CI, −31.7% to −36.4%), whereas continued SMR visit rates increased by 325.1% (95% CI, 320.2% to 342.4%). We observed a similar pattern in the South, with a −15.8% (95% CI, −15.2% to −17.0%) change in new SMR visits accompanied by a 79.1% (95% CI, 68.8% to 82.2%) increase in continued SMR visits. In the Midwest, new and continued SMR visit rates increased by 26.9% (95% CI, 22.1% to 28.9%) and 297.6% (95% CI, 273.8% to 307.5%), respectively. We observed similar but less marked increases in new and continued SMR visit rates in the West, with increases of 5.4% (95% CI, 3.8% to 5.6%) and 91.6% (95% CI, 87.4% to 93.2%), respectively.

###### 12-Year Change in SMR Utilization by Geographic Region, 2005-2016

  Age group, y[^a^](#zoi200329t3n1){ref-type="table-fn"}   No. of office visits   Age-standardized rate per million population[^b^](#zoi200329t3n2){ref-type="table-fn"}   \% Difference (95% CI)             
  -------------------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------- ------------------------ --------- -------------------------
  **New SMR visits**                                                                                                                                                                                          
  Northeast                                                806 072                604 326                                                                                  14 884                   9917      
  \<18                                                     59 485                 NR                                                                                       1142                     NR        −33.4 (−31.7 to −36.4)
  18-24                                                    142 000                NR                                                                                       2866                     NR        
  25-44                                                    171 266                112 423                                                                                  3156                     2288      
  45-64                                                    410 995                356 956                                                                                  7326                     5690      
  ≥65                                                      22 326                 134 952                                                                                  393                      1938      
  Midwest                                                  1 308 190              1 755 480                                                                                20 073                   25 466    
  \<18                                                     56 558                 NR                                                                                       863                      NR        26.9 (22.1 to 28.9)
  18-24                                                    122 191                111 327                                                                                  1928                     1667      
  25-44                                                    310 611                625 067                                                                                  4845                     10 681    
  45-64                                                    729 940                413 552                                                                                  11 048                   5642      
  ≥65                                                      88 890                 605 534                                                                                  1390                     7476      
  South                                                    3 100 314              2 433 079                                                                                22 997                   19 362    
  \<18                                                     248 784                68 892                                                                                   2314                     610       --15.8 (−15.2 to −17.0)
  18-24                                                    448 217                315 016                                                                                  4391                     2688      
  25-44                                                    984 557                201 379                                                                                  9255                     1872      
  45-64                                                    949 278                1 159 135                                                                                9181                     9270      
  ≥65                                                      469 478                688 656                                                                                  4562                     4922      
  West                                                     1 160 469              1 385 413                                                                                17 773                   18 728    
  \<18                                                     22 919                 197 263.0                                                                                321                      2752      5.4 (3.8 to 5.6)
  18-24                                                    71 311                 153 745                                                                                  1078                     2042      
  25-44                                                    373 064                396 164                                                                                  5300                     5603      
  45-64                                                    537 379                612 761                                                                                  8487                     8020      
  ≥65                                                      155 796                25 480                                                                                   2587                     311       
  Overall US                                               6 375 045              6 178 298                                                                                22 017                   18 855    --14.4 (−12.3 to −15.1)
  **Continued SMR visits**                                                                                                                                                                                    
  Northeast                                                1 324 873              5 763 559                                                                                23 768                   101 030   
  \<18                                                     NR                     NR                                                                                       NR                       NR        325.1 (320.2 to 342.4)
  18-24                                                    4466                   242 937                                                                                  90                       44 441    
  25-44                                                    339 226                2 312 550                                                                                6252                     168 064   
  45-64                                                    682 694                2 191 924                                                                                12 169                   141 183   
  ≥65                                                      298 487                1 016 148                                                                                5258                     117 659   
  Midwest                                                  1 662 278              7 086 853                                                                                25 627                   101 891   
  \<18                                                     13 411                 92 265                                                                                   205                      1461      297.6 (273.8 to 307.5)
  18-24                                                    5777                   50 600                                                                                   91                       758       
  25-44                                                    787 613                2 106 184                                                                                12 286                   35 989    
  45-64                                                    659 845                3 051 307                                                                                9987                     41 626    
  ≥65                                                      195 632                1 786 498                                                                                3058                     22 057    
  South                                                    3 641 577              7 804 048                                                                                34 745                   62 232    
  \<18                                                     NR                     NR                                                                                       NR                       NR        79.1 (68.8 to 82.2)
  18-24                                                    432                    NR                                                                                       4                        NR        
  25-44                                                    1 133 092              11 341 547                                                                               10 651                   10 544    
  45-64                                                    1 770 148              4 724 147                                                                                17 120                   37 782    
  ≥65                                                      717 800                1 945 345                                                                                6974                     13 905    
  West                                                     1 822 159              4 086 159                                                                                28 189                   54 004    
  \<18                                                     46 457                 40 390                                                                                   650                      563       91.6 (87.4 to 93.2)
  18-24                                                    NR                     64 101                                                                                   NR                       852       
  25-44                                                    513 580                951 051                                                                                  7296                     13 451    
  45-64                                                    879 499                2 424 176                                                                                13 891                   31 756    
  ≥65                                                      382 623                606 442                                                                                  6352                     7411      
  Overall US                                               8 450 887              24 740 620                                                                               29 144                   75 430    158.8 (143.2 to 164.0)

Abbreviations: NR, not reported; SMR, skeletal muscle relaxant.

Regions defined by the US Census Bureau.

2005 US population used as the reference group for age standardization.

Discussion {#H1-4-ZOI200329}
==========

This analysis of nationally representative office visit data found that SMR use doubled from 2005 to 2016 and that there was a disproportionately high use of these drugs in older adults, a population in which SMR use is potentially inappropriate. These increasing rates did not appear to have an association with the decline in opioid prescribing that began in 2012 in both the general ambulatory care population and in the older adult population.^[@zoi200329r13]^ Furthermore, among visits with a continuing SMR, 67.2% of patients were concomitantly treated with an opioid---a combination that has the potential to cause serious drug-drug interactions, such as potentiated central nervous system depression and an increased risk of opioid overdose.^[@zoi200329r9]^ As expected, among new users of SMRs, we found that the most common diagnoses were related to back pain and other musculoskeletal conditions. Interestingly, although the frequency of new initiation of SMR therapy remained stable, the number of office visits in which SMR therapy was continued tripled, indicating a potential shift in duration of use of these drugs. This trend is a concern given the limited evidence of long-term efficacy and the risk of serious central nervous system adverse effects and drug-drug interactions.

Although prior papers have examined the use of SMRs in veterans^[@zoi200329r4]^ and older adults,^[@zoi200329r14],[@zoi200329r15]^ the present study is, to our knowledge, the first study since 2004^[@zoi200329r5],[@zoi200329r16]^ to examine SMR use in the general population. The strengths of this study stem from the design of the NAMCS that permits us to make projections to US physician office visits.

Limitations {#H2-1-ZOI200329}
-----------

This study has some limitations. The NAMCS does not capture patients leaving the hospital with an SMR prescription or allow researchers to follow patients over time or assess clinical outcomes. In addition, these data are limited to the United States, and we are unaware of recent analogous data from other countries.

Conclusions {#H1-5-ZOI200329}
===========

Given their prominent adverse effects and the limited evidence for their long-term efficacy, growth in the continued use of SMRs, particularly in older adults and concomitantly with opioids, is concerning. Given the findings of this cross-sectional study, efforts to limit the long-term use of SMRs may be needed, especially for older adults, similar to efforts used to limit the long-term use of opioids^[@zoi200329r17]^ and benzodiazepines.^[@zoi200329r18]^

###### 

**eTable 1.** NAMCS Variable and Population of Analysis

**eTable 2.** Number of US Office Visits with a Skeletal Muscle Relaxant Prescription, 2005-2016

**eTable 3.**Office Visits With Newly Prescribed or Continued Opioid Therapy, 2016
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Click here for additional data file.
